ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial
- Resource Type
- Article
- Authors
- Mounier, N. ; Brice, P.; Bologna, S.; Briere, J.; Gaillard, I.; Heczko, M.; Gabarre, J.; Casasnovas, O.; Jaubert, J.; Colin, P.; Delmer, A.; Devidas, A.; Bachy, E.; Nicolas-Virelizier, E.; Aoudjhane, A.; Humbrecht, C.; Andre, M.; Carde, P.
- Source
- In Annals of Oncology August 2014 25(8):1622-1628
- Subject
- Language
- ISSN
- 0923-7534